Why Psoriasis Is Not the Same Disease in Every Patient

Examine the clinical and biological heterogeneity of psoriasis and how differences in inflammatory activity, genetic susceptibility, and tissue-level biology may contribute to variability in disease presentation, course, and treatment response.

Clinical Heterogeneity Is Observable 

Although psoriasis affects approximately 1% to 3% of individuals worldwide and is one of the most common inflammatory skin diseases, its morphology, distribution, and severity can vary dramatically.^1,2 Two patients with the same diagnosis may differ markedly in clinical presentation. Differences can include age of disease onset, lesion location (localized vs widespread), and appearance (eg, plaques, papules, or erythema and scale).^2,3 Symptom burden is similarly heterogeneous. Itch and pain are reported by a majority of patients with psoriasis, though the intensity can vary considerably among individuals.^4,5 This clinical variability illustrates that psoriasis is not a uniform disease and that heterogeneity is observable well before molecular analysis. 

Heterogeneity Extends Beyond What’s Visible 

Research suggests that psoriasis stems from a combination of inherited genetic susceptibility and environmental triggers. More than 80 genetic regions have been implicated, though HLA-Cw6 shows the strongest association, particularly in earlier disease onset and greater severity.^1,2,6-8 Similarly, there are a wide range of environmental triggers, including infection, trauma (Koebner phenomenon), stress, sun exposure, or drugs, among others.^1,8 In predisposed individuals, environmental triggers can initiate inflammatory responses in the skin. Activated dendritic cells produce cytokines that promote T-cell responses, including type 17 responses.^8,9 Cytokines produced by these immune cells act on keratinocytes, contributing to epidermal hyperproliferation and other changes characteristic of psoriatic lesions. The stimulated keratinocytes, in turn, produce inflammatory mediators that can further recruit and activate immune cells, helping perpetuate the inflammatory cycle.^8,10 The IL-23/IL-17 axis has a well-established central role in psoriasis pathogenesis, but it functions within a broader network of immune cells, inflammatory mediators, and reciprocal interactions with kerotinocytes.⁸  

Psoriasis Heterogeneity Extends Beyond Clinical Presentation  

Why Disease Biology May Differ Among Patients 

In recent years, single-cell transcriptomic and proteomic work has revealed interpatient variability in immune cell populations and activity, such as distinct dendritic cell and T-cell subsets, and composition of the skin immune microenvironment, including differences in endothelial cell activity and cell communication.^8-10 With advances in single-cell and molecular profiling, candidate endotypes have been proposed with psoriasis and linked to differences in disease severity and treatment response.^11,12 Despite promising candidate biomarkers and omics approaches, findings remain inconsistent across studies, and none have yet been validated for routine use in precision disease management.^12,13   

Clinical Heterogeneity May Help Explain Variable Outcomes 

Differences in underlying inflammatory biology may contribute to variation in disease expression and treatment response. Despite the availability of numerous biologic therapies, responses vary considerably among patients and may be influenced by multiple factors, including differences in underlying disease biology.¹² This variability may be evident not only at the molecular and cellular levels, but also in the disease burden experienced and reported by patients. Notably, burden does not necessarily align with visible severity and can be compounded by comorbidity profiles that differ just as widely from patient to patient.^1,7  

Why a Single Pathway Model Is Incomplete 

The clinical understanding of psoriasis has evolved considerably in recent years. It was once viewed primarily as a disorder of keratinocyte hyperproliferation, but advances in understanding its pathogenesis have revealed complex interactions between immune activation and keratinocyte response.⁹ One clearly established route is the IL-23/IL-17 signaling axis, which plays a major role in disease progression.^8,9 However, as research progresses, this model continues to be refined. As additional signaling components are identified, from other T-cell subsets to keratinocyte-derived signaling, it becomes increasingly evident that understanding psoriasis biology requires considering how these components interact, rather than viewing any one pathway in isolation.^8,9  

Clinical Takeaway 

Heterogeneity is visible, not only at the bedside but increasingly evident at the cellular and molecular levels. Current technology does not yet allow routine molecular stratification of individual patients, but recognizing psoriasis as a biologically complex disease provides a more accurate framework for understanding variability in presentation and outcomes.

References

1. Mehta S, Sathe NC. Plaque psoriasis. In: StatPearls. StatPearls Publishing; 2025. Updated September 14, 2025. Accessed August 17, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430879/ 
2. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-ii23. doi:10.1136/ard.2004.033217 
3. Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392-398. doi:10.5114/reum.2018.80718 
4. Taliercio VL, Snyder AM, Webber LB, et al. The disruptiveness of itchiness from psoriasis: a qualitative study of the impact of a single symptom on quality of life. J Clin Aesthet Dermatol. 2021;14(6):42-48. 
5. Snyder AM, Taliercio VL, Webber LB, et al. The role of pain in the lives of patients with psoriasis: a qualitative study on an inadequately addressed symptom. J Psoriasis Psoriatic Arthritis. 2022;7(1):29-34. doi:10.1177/24755303211066928  
6. Dhabale A, Shailesh N. Types of psoriasis and their effects on the immune system. Cureus. 14(9): e29536. doi: 10.7759/cureus.29536 
7. Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25-33. doi:10.2147/PTT.S328447 
8. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7 
9. Gooderham MJ, Papp KA, Lynde CW. Shifting the focus — the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1119. doi:10.1111/jdv.14868 
10. Cui N, Xu X, Zhou F. Single-cell technologies in psoriasis. Clin Immunol. 2024;264:110242. doi:10.1016/j.clim.2024.110242 
11. Rider A, Grantham HJ, Smith GR, et al. Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity. Coms Med. 2026;6:65 doi:10.1038/s43856-025-01325-4 
12. Zhang S, Chang M, Zheng L, et al. Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis. Front Immunol. 2024;15:1326502. doi:10.3389/fimmu.2024.1326502 
13. Chandran V, Liao W, de Vlam K. Biomarkers in psoriasis and psoriatic arthritis: where are we now? J Rheumatol. 2024;51(Suppl 2):74-76. doi:10.3899/jrheum.2024-0260